Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk

American Journal of Epidemiology

Volumn 165, Issue 10, 2007, Pages 1187-1198

  Shantakumar, Sumitra ^a,h   Terry, Mary Beth ^b   Paykin, Andrea ^c   Teitelbaum, Susan L ^d   Britton, Julie A ^d   Moorman, Patricia G ^e   Kritchevsky, Stephen B ^f   Neugut, Alfred I ^b,g   Gammon, Marilie D ^a  

^a IL   (United States)

^b Columbia University ^*  (United States)

^c NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

^g GlaxoSmithKline Research and Development ^*  (United States)

^h GLAXOSMITHKLINE   (United States)

Author keywords

Aged; Breast neoplasms; Contraceptives, oral; Hormone replacement therapy; Perimenopause; Postmenopause; Premenopause; Progestins

Indexed keywords

ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

AGE STRUCTURE; BODY CONDITION; CANCER; CONTRACEPTIVE USE; HEALTH RISK; HEALTH STATUS; HORMONE; WOMENS HEALTH;

ADULT; AGED; ARTICLE; BIRTH CONTROL; BREAST CANCER; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEALTH HAZARD; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MEMORY; MENOPAUSAL SYNDROME; MENOPAUSE; ONSET AGE; POSTMENOPAUSE; PREMENOPAUSE; AGE; BREAST TUMOR; CASE CONTROL STUDY; MIDDLE AGED; RISK FACTOR;

LONG ISLAND [NEW YORK]; NEW YORK [UNITED STATES]; NORTH AMERICA; UNITED STATES;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; MIDDLE AGED; RISK FACTORS;

EID: 34447115713     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwm006     Document Type: Article

References (65)

1. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1996;347:1713-27.
2. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997;350:1047-59.
3. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:58-66.
4. Rossouw JE, Anderson GL, Prentice RL, et al. Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized control trial. JAMA 2002;288:321-33.
5. Cogliano V, Grosse Y, Baan R, et al. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 2005;6:552-3.
6. Norman S, Berlin JA, Weber AL, et al. Combined effect of oral contraceptive use and hormone replacement therapy on breast cancer risk in postmenopausal women. Cancer Causes Control 2003;14:933-43.
7. Mills P, Beeson WL, Phillips RL, et al. Prospective study of exogenous hormone use and breast cancer in Seventh-day Adventists. Cancer 1989;64:591-7.
8. Olsson H, Bladstrom A, Ingvar C, et al. A population-based cohort study of HRT use and breast cancer in southern Sweden. Br J Cancer 2001;85:674-7.
9. Stanford J, Brinton LA, Hoover RN. Oral contraceptives and breast cancer: results from an expanded case-control study. Br J Cancer 1989;60:375-81.
10. Stanford J, Weiss NS, Voigt LF, et al. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995;274:137-42.
11. Schuurman A, van den Brandt PA, Goldbohm RA. Exogenous hormone use and the risk of postmenopausal breast cancer: results from the Netherlands Cohort Study. Cancer Causes Control 1995;6:416-24.
12. Ursin G, Tseng CC, Paganini-Hill A, et al. Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer? J Clin Oncol 2002;20:699-706.
13. Brinton L, Brogan DR, Coates RJ, et al. Breast cancer risk among women under 55 years of age by joint effects of usage of oral contraceptives and hormone replacement therapy. Menopause 1998;5:145-51.
14. Gammon M, Neugut AI, Santella RM, et al. The Long Island Breast Cancer Study Project: description of a multi-institutional collaboration to identify environmental risk factors for breast cancer. Breast Cancer Res Treat 2002;3:235-54.
15. Waksberg J. Sampling methods for random digit dialing. J Am Stat Assoc 1978;73:40-6.
16. Hosmer D, Lemeshow S. Applied logistic regression. New York, NY: John Wiley & Sons, Inc, 1989.
17. Rothman K, Greenland S. Modern epidemiology. Philadelphia, PA: Lippincott-Raven, 1998.
18. Shantakumar S, Terry MB, Teitelbaum SL, et al. Reproductive factors and breast cancer risk among older women. Breast Cancer Res Treat (in press).
19. Hesch RD, Kenemans P. Hormonal prevention of breast cancer: proposal for a change in paradigm. Br J Obstet Gynaecol 1999;106:1006-18.
20. Key TJ, Pike MC. The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 1988;24:29-43.
21. Manjer J, Johansson R, Berglund G, et al. Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and SHBG (Sweden). Cancer Causes Control 2003;14:599-607.
22. Raafat A, Hofseth LJ, Li S, et al. A mouse model to study the effects of hormone replacement therapy on normal mammary gland during menopause: enhanced proliferative response to estrogen in late postmenopausal mice. Endocrinology 1999;140:2570-80.
23. Pasqualini J, Paris J, Sitruk-Ware R, et al. Progestins and breast cancer. J Steroid Biochem Mol Biol 1998;65:225-35.
24. Kirsh V, Kreiger N. Estrogen and estrogen-progestin replacement therapy and risk of postmenopausal breast cancer in Canada. Cancer Causes Control 2002;13:583-90.
25. Jernstrom H, Bendahl PO, Lidfeldt J, et al. A prospective study of different types of hormone replacement therapy use and the risk of subsequent breast cancer: the Women's Health in the Lund Area (WHILA) Study (Sweden). Cancer Causes Control 2003;14:673-80.
26. Porch J, Lee IM, Cook NR, et al. Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United States). Cancer Causes Control 2002;13:847-54.
27. Magnusson C, Baron JA, Correia N, et al. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 1999;81:339-44.
28. Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-91.
29. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
30. Persson I, Yuen J, Bergkvist L, et al. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - long-term follow-up of a Swedish cohort. Int J Cancer 1996;67:327-32.
31. Olsson H, Ingvar C, Bladstrom A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 2003;97:1387-92.
32. Weiss L, Burkman RT, Cushing-Haugen KL, et al. Hormone replacement therapy regimens and breast cancer risk. Obstet Gynecol 2002;100:1148-58.
33. Ross R, Paganini-Hill A, Wan PC, et al. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328-32.
34. Newcomb P, Titus-Ernstoff L, Egan KM, et al. Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:593-600.
35. Chlebowski R, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-53.
36. Hormonal contraception and post-menopausal hormonal therapy. Lyon, France: International Agency for Research on Cancer, 1999.
37. Marchbanks P, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002;346:2025-32.
38. Kelsey J. Breast cancer epidemiology: summary and future directions. Epidemiol Rev 1993;15:256-63.
39. Rookus M, van Leeuwen FE. Oral contraceptives and risk of breast cancer in women aged 20-54 years. Netherlands Oral Contraceptives and Breast Cancer Study Group. Lancet 1994;344:844-51.
40. Rosenberg L, Palmer JR, Clarke EA, et al. A case-control study of the risk of breast cancer in relation to oral contraceptive use. Am J Epidemiol 1992;136:1437-44.
41. Rossing M, Stanford JL, Weiss NS, et al. Oral contraceptive use and risk of breast cancer in middle-aged women. Am J Epidemiol 1996;144:161-4.
42. Magnusson C, Persson IR, Baron JA, et al. The role of reproductive factors and use of oral contraceptives in the aetiology of breast cancer in women aged 50 to 74 years. Int J Cancer 1999;80:231-6.
43. Van Hoften C, Burger H, Peeters PH, et al. Long-term oral contraceptive use increases breast cancer risk in women over 55 years of age: the DOM cohort. Int J Cancer 2000;87:591-4.
44. Rosenberg L, Palmer JR, Rao RS, et al. Case-control study of oral contraceptive use and risk of breast cancer. Am J Epidemiol 1996;143:25-37.
45. Ewertz M. Oral contraceptives and breast cancer risk in Denmark. Eur J Cancer 1992;28A:1176-81.
46. Petitti DB, Perlman JA. Re: "A prospective cohort study of postmenopausal hormone use and risk of breast cancer in US women." (Letter). Am J Epidemiol 1988;127:883.
47. Hammar M, Brynhildsen J, Dabrosin L, et al. Hormone replacement therapy and previous use of oral contraceptives among Swedish women. Maturitas 1996;25:193-9.
48. Dumeaux V, Fournier A, Lund E, et al. Previous oral contraceptive use and breast cancer risk according to hormone replacement therapy use among postmenopausal women. Cancer Causes Control 2005;16:537-44.
49. Pike M, Ross RK, Spicer DV. Problems involved in including women with simple hysterectomy in epidemiologic studies measuring the effects of hormone replacement therapy on breast cancer risk. Am J Epidemiol 1998;147:718-21.
50. Merlo J, Berglund G, Wirfalt E, et al. Self-administered questionnaire compared with a personal diary for assessment of current use of hormone therapy: an analysis of 16,060 women. Am J Epidemiol 2000;152:788-92.
51. Hunter D, Manson JE, Colditz GA, et al. Reproducibility of oral contraceptive histories and validity of hormone composition reported in a cohort of US women. Contraception 1997;56:373-8.
52. Goodman M, Nomura AM, Wilkens LR, et al. Agreement between interview information and physician records on history of menopausal estrogen use. Am J Epidemiol 1990;131:815-25.
53. Paganini-Hill A, Ross RK. Reliability of recall of drug usage and other health-related information. Am J Epidemiol 1982;116:114-22.
54. Bergkvist L, Adami HO, Persson I, et al. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989;321:293-7.
55. Brinton L, Hoover RN, Szklo M, et al. Menopausal estrogen use and risk of breast cancer. Cancer 1981;47:2517-22.
56. Boudreau D, Daling JR, Malone KE, et al. A validation study of patient interview data and pharmacy records for antihypertensive, statin, and antidepressant medication use among older women. Am J Epidemiol 2004;159:308-17.
57. Sjahid S, van der Linden PD, Stricker BH. Agreement between the pharmacy medication history and patient interview for cardiovascular drugs: the Rotterdam elderly study. Br J Clin Pharmacol 1988;45:591-5.
58. Master-Hunter T, Heiman DL. Amenorrhea: evaluation and treatment. Am Fam Physician 2006;73:1374-82.
59. Pierce S, Gazvani MR, Farquharson RG. Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up. Fertil Steril 2000;74:964-8.
60. Avis N, Stellato R, Crawford S, et al. Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups. Soc Sci Med 2001;52:345-56.
61. Shapiro S. Bias in the evaluation of low-magnitude associations: an empirical perspective. Am J Epidemiol 2000;151:939-45.
62. Sturgeon S, Schairer C, Brinton LA, et al. Evidence of a healthy estrogen user survivor effect. Epidemiology 1995;6:227-31.
63. US Preventive Services Task Force. Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationale. Ann Intern Med 2002;137:834-9.
64. Committee on Safety of Medicines. Review of the evidence on the long-term safety of HRT. Curr Probl Pharmacovigilance 2004;30:4-7.
65. The European Agency for the Evaluation of Medicinal Products. Guideline for hormone replacement therapy. London, United Kingdom: European Medicines Agency, January 20, 2005. (http://www.emea.eu.int/pdfs/human/ewp/002197en.pdf). Accessed July 7, 2005.